Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms

• US 6,495,601 B1
• Filed: 12/22/1999
• Issued: 12/17/2002
• Est. Priority Date: 12/23/1998
• Status: Expired due to Fees

• Current Assignee: NeuroTherapeutics Pharma, Inc.
• Original Assignee: Cytoscan Sciences, LLC
• Inventors: Hochman, Daryl W.
• Primary Examiner(s): Fay, Zohreh
• Assistant Examiner(s): KWON, YONG SOK
• Application Number:
  US09/470,637
• Time in Patent Office: 1,091 Days
• Field of Search: 514/603, 514/562, 514/269, 435/29
• US Class Current: 514/562
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/635 having a heterocyclic ring, e.g. sulfadiazine

Abstract

The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for treating seizure and seizure disorders, epilepsy, status epilepticus, migraine, spreading depression, intracranial hypertension; for treating the pathophysiological effects of head trauma, stroke, ischemia and hypoxia; for treating or protecting from the pathophysiological effects of neurotoxic agents such as ethanol; and for treating neurophsyciatric disorders and central nervous system edema by administering agents that modulate ionic concentrations and/or ionic gradients in the brain, particularly ion-dependent or cation-chloride cotransporter antagonists. Ion-dependent cotransport antagonists and combinations of such compositions with other agents for treating various conditions are disclosed. The present invention also relates to methods and compositions for treating pain by administering ion-dependent cotransporter antagonists. Methods and compositions for enhancing cortical function, for example, in centers of cognition, learning and memory, by administering ion-dependent cotransporter agonists are disclosed. Methods and systems for screening drug candidate compounds for desired activities using in vitro and in vivo systems are disclosed.

Claims

1. A method for treating a condition of the central nervous system in a mammalian subject in need thereof comprising delivering an effective amount of a treatment composition comprising a Na⁺K⁺Cl⁻

cotransporter antagonist to the subject'"'"'s central nervous system, wherein the condition is selected from the group consisting of seizures, seizure disorders, epilepsy and status epilepticus, and wherein the treatment composition has higher activity as a glial cell ion-dependent cotransporter antagonist than as a neuronal cell ion-dependent cotransporter antagonist.

5. The method of claim 1, wherein the Na⁺K⁺Cl⁻

cotransporter antagonist is delivered to the central nervous system by one or more of the following;

intracranial administration, local intracerebral administration, administration into the cerebral spinal fluid, administration in a sustained release formulation, or formulated to facilitate crossing of the blood brain barrier.

2. A method for treating a condition of the central nervous system selected from the group consisting of seizures, seizure disorders, epilepsy and status epilepticus in a mammalian subject in need thereof, consisting essentially of delivering an effective amount of a loop diuretic to the central nervous system, wherein the loop diuretic has higher activity in a central nervous system cell population than in a renal cell population.

3. A method for treating a condition of the central nervous system selected from the group consisting of seizures, seizure disorders, epilepsy and status epilepticus in a mammalian subject in need thereof, consisting essentially of delivering an effective amount of a Na⁺K⁺Cl⁻

antagonist to the central nervous system.

4. A method for treating a condition of the central nervous system in a mammalian subject in need thereof comprising delivering an effective amount of a treatment composition comprising a loop diuretic to the subject'"'"'s central nervous system, wherein the condition is selected from the group consisting of seizures, seizure disorders, epilepsy and stanza epilepticus, and wherein the treatment composition has higher activity as a glial cell iondependent cotransporter antagonist than as a neuronal cell ion-dependent cotransporter antagonist.

6. The method of claim 4, wherein the loop diuretic is delivered to the central nervous system by one or more of the following:

intracranial administration, local intracerebral administration, administration into the cerebral spinal fluid, administration in a